RICHMOND, Va., Feb 4, 2004 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) a developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs, will announce fourth quarter and full year financial results Wednesday, February 11, before market open.
The Company will host a conference call on Wednesday, February 11, at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Company management will conduct the call that will highlight the performance expectations of the company and the ongoing pivotal Phase III trial with rhIGF-I/rhIGFBP-3 in GHIS.
To participate in the conference call dial 800-915-4836 (domestic) or 973-317- 5319 (international). The call will be webcast live through Insmed's corporate website: www.insmed.com.
A telephonic replay of the call will be available for one week at 800-428-6051 (domestic) or 973-709-2089 (international), passcode: 334672. A web replay of the call will be available through the corporate website beginning at 1:00 p.m.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. For further information about Insmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at www.insmed.com.
